ENTRY       D00661                      Drug
NAME        Cevimeline hydrochloride (USAN);
            Cevimeline hydrochloride hydrate (JAN);
            Evoxac (TN);
            Saligren (TN)
PRODUCT     CEVIMELINE (Sun Pharmaceutical Industries)
            CEVIMELINE HYDROCHLORIDE (Cosette Pharmaceuticals)
            EVOXAC (Cosette Pharmaceuticals)
            EVOXAC (Daiichi Sankyo)
  GENERIC   CEVIMELINE HYDROCHLORIDE (Advagen Pharma)
            CEVIMELINE HYDROCHLORIDE (Aurobindo Pharma Limited)
            CEVIMELINE HYDROCHLORIDE (Hikma Pharmaceuticals USA)
            CEVIMELINE HYDROCHLORIDE (Lupin Pharmaceuticals)
            CEVIMELINE HYDROCHLORIDE (Novel Laboratories)
            CEVIMELINE HYDROCHLORIDE (Rising Pharma Holdings)
FORMULA     (C10H17NOS)2. 2HCl. H2O
EXACT_MASS  488.1701
MOL_WEIGHT  489.5633
CLASS       Neuropsychiatric agent
             DG01490  Muscarinic cholinergic receptor agonist
             DG01719  Parasympathomimetic agent
            Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2399
            ATC code: N07AX03
            Chemical structure group: DG00993
            Product (DG00993): D00661<JP/US>
EFFICACY    Salivation accelaletor, Muscarinic acetylcholine receptor agonist
  DISEASE   Sj√∂gren's Syndrome [DS:H01502]
COMMENT     Arecoline derivative
TARGET      CHRM3 [HSA:1131] [KO:K04131]
  PATHWAY   hsa04080(1131)  Neuroactive ligand-receptor interaction
            hsa04725(1131)  Cholinergic synapse
            hsa04970(1131)  Salivary secretion
METABOLISM  Enzyme: CYP2D6 [HSA:1565], CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N07 OTHER NERVOUS SYSTEM DRUGS
               N07A PARASYMPATHOMIMETICS
                N07AX Other parasympathomimetics
                 N07AX03 Cevimeline
                  D00661  Cevimeline hydrochloride (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Dental and Oral Agents
              Cevimeline
               D00661  Cevimeline hydrochloride (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              23  Digestive organ agents
               239  Miscellaneous
                2399  Others
                 D00661  Cevimeline hydrochloride (USAN); Cevimeline hydrochloride hydrate (JAN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01490  Muscarinic cholinergic receptor agonist
               DG00993  Cevimeline
                D00661  Cevimeline hydrochloride
              DG01719  Parasympathomimetic agent
               DG00993  Cevimeline
                D00661  Cevimeline hydrochloride
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG00993  Cevimeline
                D00661  Cevimeline hydrochloride
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00993  Cevimeline
                 D00661  Cevimeline hydrochloride
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Acetylcholine (muscarinic)
                CHRM3
                 D00661  Cevimeline hydrochloride (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D00661
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D00661
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D00661
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D00661
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D00661
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01490  Muscarinic cholinergic receptor agonist
               DG00993  Cevimeline
              DG01719  Parasympathomimetic agent
               DG00993  Cevimeline
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG00993  Cevimeline
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00993  Cevimeline
DBLINKS     CAS: 153504-70-2
            PubChem: 7847727
            ChEBI: 3568
            LigandBox: D00661
            NIKKAJI: J1.915.230H
ATOM        29
            1   C1z C    24.9536  -15.4572
            2   C1y C    24.9536  -14.0450
            3   C1x C    23.6698  -16.2274
            4   C1x C    23.6698  -13.2748
            5   C1x C    24.0550  -14.9437
            6   N1y N    22.3861  -15.4572
            7   C1x C    22.3861  -14.0450
            8   C1x C    23.4130  -14.4302
            9   O2x O    24.9536  -16.8968
            10  C1y C    26.3228  -17.3417
            11  S2x S    27.1689  -16.1770
            12  C1x C    26.3228  -15.0123
            13  C1a C    26.7689  -18.7147
            14  O0  O    31.1826  -14.4759
            15  X   Cl   31.0386  -16.9232
            16  C1z C    24.9536  -15.4572
            17  C1y C    24.9536  -14.0450
            18  C1x C    23.6698  -13.2748
            19  C1x C    22.3861  -14.0450
            20  N1y N    22.3861  -15.4572
            21  C1x C    23.6698  -16.2274
            22  C1x C    23.4130  -14.4302
            23  C1x C    24.0550  -14.9437
            24  O2x O    24.9536  -16.8968
            25  C1y C    26.3228  -17.3417
            26  S2x S    27.1689  -16.1770
            27  C1x C    26.3228  -15.0123
            28  C1a C    26.7689  -18.7147
            29  X   Cl   31.0386  -16.9232
BOND        30
            1     1   2 1
            2     1   3 1
            3     2   4 1
            4     2   5 1
            5     3   6 1
            6     4   7 1
            7     5   8 1
            8     6   7 1
            9     6   8 1
            10    1   9 1 #Up
            11    9  10 1
            12   10  11 1
            13   11  12 1
            14    1  12 1
            15   10  13 1 #Down
            16   16  17 1
            17   16  21 1
            18   17  18 1
            19   17  23 1
            20   21  20 1
            21   18  19 1
            22   23  22 1
            23   20  19 1
            24   20  22 1
            25   16  24 1 #Up
            26   24  25 1
            27   25  26 1
            28   26  27 1
            29   16  27 1
            30   25  28 1 #Down
BRACKET     1    21.7000  -19.3900   21.7000  -12.8100
            1    28.1400  -12.8100   28.1400  -19.3900
            1  2
  ORIGINAL  1    1   2   4   7   6   3   8   5   9  10  11  12  13
  REPEAT    1   16  17  18  19  20  21  22  23  24  25  26  27  28
            2    29.4700  -17.7800   29.4700  -15.9600
            2    31.7100  -15.9600   31.7100  -17.7800
            2  2
  ORIGINAL  2   15
  REPEAT    2   29
///
